Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after depression treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of depression and related therapies
as they heal people who benefited from our expertise.
Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake.
August 2010
/ onclick=”MoreLine(‘11688’, ‘Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake.’)”>
…more
/>Biomed Res. 2010 Aug ;31(4):231-7. PMID: 20834180
Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.
June 2015
/ onclick=”MoreLine(‘11687’, ‘Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.’)”>
…more
/>Wien Med Wochenschr. 2015 Jun 20. Epub 2015 Jun 20. PMID: 26092515
Isoquinoline derivatives isolated from the fruit of Annona muricata as 5-HTergic 5-HT1A receptor agonists in rats: unexploited antidepressive (lead) products.
November 1997
/ onclick=”MoreLine(‘11618’, ‘Isoquinoline derivatives isolated from the fruit of Annona muricata as 5-HTergic 5-HT1A receptor agonists in rats: unexploited antidepressive (lead) products.’)”>
…more
/>J Pharm Pharmacol.1997 Nov;49(11):1145-9 PMID: 9401954
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.
December 2015
/ onclick=”MoreLine(‘11113’, ‘The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.’)”>
…more
/>Neuroimage Clin. 2016 ;11:53-60. Epub 2015 Aug 22. PMID: 26909323
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
June 2016
Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression.
METHODS:
In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin’s effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797. FINDINGS: Psilocybin’s acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges’ g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges’ g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted. INTERPRETATION: This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. FUNDING: Medical Research Council.
/ onclick=”MoreLine(‘9395’, ‘Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.’)”>
…more
/>Lancet Psychiatry. 2016 Jul ;3(7):619-27. Epub 2016 May 17. PMID: 27210031
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
October 2015
The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change.
METHODS:
This study assessed the effects of acute administration of the hallucinogen psilocybin (.16 mg/kg) versus placebo on amygdala reactivity to negative stimuli in 25 healthy volunteers using blood oxygen level-dependent functional magnetic resonance imaging. Mood changes were assessed using the Positive and Negative Affect Schedule and the state portion of the State-Trait Anxiety Inventory. A double-blind, randomized, cross-over design was used with volunteers counterbalanced to receive psilocybin and placebo in two separate sessions at least 14 days apart.
Results:
Amygdala reactivity to negative and neutral stimuli was lower after psilocybin administration than after placebo administration. The psilocybin-induced attenuation of right amygdala reactivity in response to negative stimuli was related to the psilocybin-induced increase in positive mood state. CONCLUSIONS: These results demonstrate that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. These findings may be relevant to the normalization of amygdala hyperactivity and negative mood states in patients with major depression.
/ onclick=”MoreLine(‘9394’, ‘Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.’)”>
…more
/>Biol Psychiatry. 2015 Oct 15 ;78(8):572-81. Epub 2014 Apr 26. PMID: 24882567